Conatus Pharmaceuticals Initiates Phase 2b Trial of Emricasan in Acute-on-Chronic Liver Failure (ACLF) Patients

Conatus Pharmaceuticals (Nasdaq: CNAT ), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced initiation of active patient recruitment in a Phase 2b clinical trial of emricasan in patients with acute-on-chronic liver failure (ACLF). The placebo-controlled, double-blind, multicenter clinical trial